BACKGROUND: von Willebrand Factor (VWF) is tightly regulated by the metalloproteinase ADAMTS13, which cleaves VWF to reduce VWF multimer size and binding affinity for collagen and platelets. OBJECTIVE: This study examines two VWF mutations, R1597W (enhanced cleavage) and Y1605A-M1606A (decreased cleavage), to determine their impact on VWF, in addition to ADAMTS13-mediated cleavage. METHODS: In vitro mouse ADAMTS13 digestions were performed on recombinant proteins. VWF knockout mice received hydrodynamic injections of mouse Vwf cDNA, following which VWF antigen, multimer profile and VWF propeptide levels were determined. A ferric chloride injury model of thrombosis was also evaluated. RESULTS: In vitro ADAMTS13 digestion of full-length mouse VWF required > 97-fold higher ADAMTS13 levels for Y1605A/M1606A, and 68% lower ADAMTS13 levels for R1597W compared with wild type. In vivo, R1597W had reduced VWF:Ag and both mutations exhibited increased VWF propeptide/VWF:Ag ratios. R1597W multimers show a lower molecular weight profile compared with wild type and Y1605A/M1606A mice. When co-injected with Adamts13 cDNA, Y1605A/M1606A multimers were larger compared with wild type, and R1597W showed only a single multimer band and decreased clearance via VWFpp/VWF:Ag ratio. R1597W was associated with reduced thrombus formation but normal platelet accumulation in a ferric chloride injury model while Y1605A/M1606A had a loss of occlusive thrombi but increased platelet accumulation compared with wild type. CONCLUSIONS: This study demonstrates that mutations that alter ADAMTS13 cleavage also can affect VWF clearance, VWF antigen level, multimer structure and thrombotic potential in the VWF knockout hydrodynamic injection model.
BACKGROUND:von Willebrand Factor (VWF) is tightly regulated by the metalloproteinase ADAMTS13, which cleaves VWF to reduce VWF multimer size and binding affinity for collagen and platelets. OBJECTIVE: This study examines two VWF mutations, R1597W (enhanced cleavage) and Y1605A-M1606A (decreased cleavage), to determine their impact on VWF, in addition to ADAMTS13-mediated cleavage. METHODS: In vitro mouseADAMTS13 digestions were performed on recombinant proteins. VWF knockout mice received hydrodynamic injections of mouseVwf cDNA, following which VWF antigen, multimer profile and VWFpropeptide levels were determined. A ferric chloride injury model of thrombosis was also evaluated. RESULTS: In vitro ADAMTS13 digestion of full-length mouseVWF required > 97-fold higher ADAMTS13 levels for Y1605A/M1606A, and 68% lower ADAMTS13 levels for R1597W compared with wild type. In vivo, R1597W had reduced VWF:Ag and both mutations exhibited increased VWFpropeptide/VWF:Ag ratios. R1597W multimers show a lower molecular weight profile compared with wild type and Y1605A/M1606A mice. When co-injected with Adamts13 cDNA, Y1605A/M1606A multimers were larger compared with wild type, and R1597W showed only a single multimer band and decreased clearance via VWFpp/VWF:Ag ratio. R1597W was associated with reduced thrombus formation but normal platelet accumulation in a ferric chloride injury model while Y1605A/M1606A had a loss of occlusive thrombi but increased platelet accumulation compared with wild type. CONCLUSIONS: This study demonstrates that mutations that alter ADAMTS13 cleavage also can affect VWF clearance, VWF antigen level, multimer structure and thrombotic potential in the VWF knockout hydrodynamic injection model.
Authors: Cynthia M Pruss; Mia Golder; Andrea Bryant; Carol A Hegadorn; Erin Burnett; Kimberly Laverty; Kate Sponagle; Aly Dhala; Colleen Notley; Sandra Haberichter; David Lillicrap Journal: Blood Date: 2011-02-23 Impact factor: 22.113
Authors: K Bruno; D Völkel; B Plaimauer; G Antoine; S Pable; D G Motto; H L Lemmerhirt; F Dorner; K Zimmermann; F Scheiflinger Journal: J Thromb Haemost Date: 2005-05 Impact factor: 5.824
Authors: Cynthia M Pruss; Colleen R P Notley; Carol A Hegadorn; Lee A O'Brien; David Lillicrap Journal: Br J Haematol Date: 2008-11 Impact factor: 6.998
Authors: Barbara Plaimauer; Klaus Zimmermann; Dirk Völkel; Gerhard Antoine; Randolf Kerschbaumer; Pegah Jenab; Miha Furlan; Helen Gerritsen; Bernhard Lämmle; Hans Peter Schwarz; Friedrich Scheiflinger Journal: Blood Date: 2002-07-12 Impact factor: 22.113
Authors: Scott Cooper; Shawn Sell; Luke Nelson; Jennifer Hawes; Jacob A Benrud; Bridget M Kohlnhofer; Bradley R Burmeister; Veronica H Flood Journal: J Comp Physiol B Date: 2016-01 Impact factor: 2.200
Authors: Veronica H Flood; Abraham C Schlauderaff; Sandra L Haberichter; Tricia L Slobodianuk; Paula M Jacobi; Daniel B Bellissimo; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Raymond G Hoffmann; Robert R Montgomery Journal: Blood Date: 2015-02-06 Impact factor: 22.113
Authors: Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap Journal: Blood Adv Date: 2021-02-09
Authors: Karl C Desch; Colin Kretz; Andrew Yee; Robert Gildersleeve; Kristin Metzger; Nidhi Agrawal; Jane Cheng; David Ginsburg Journal: PLoS One Date: 2015-04-07 Impact factor: 3.240
Authors: Yasuaki Shida; Laura L Swystun; Christine Brown; Jeffrey Mewburn; Kate Nesbitt; Ozge Danisment; Jonathan Jacob Riches; Christine Hough; David Lillicrap Journal: Res Pract Thromb Haemost Date: 2019-03-23
Authors: Richard D Starke; Koralia E Paschalaki; Clare E F Dyer; Kimberly J Harrison-Lavoie; Jacqueline A Cutler; Thomas A J McKinnon; Carolyn M Millar; Daniel F Cutler; Mike A Laffan; Anna M Randi Journal: Blood Date: 2013-01-25 Impact factor: 22.113
Authors: Alexander Leatherdale; D'Andra Parker; Subia Tasneem; Yiming Wang; Dominique Bihan; Arkadiusz Bonna; Samir W Hamaia; Peter L Gross; Heyu Ni; Bradley W Doble; David Lillicrap; Richard W Farndale; Catherine P M Hayward Journal: J Thromb Haemost Date: 2020-12-17 Impact factor: 5.824